Veracyte, Inc.

450 articles about Veracyte, Inc.

• Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting

  4/27/2023

  Veracyte, Inc. (Nasdaq: VCYT) today announced that five abstracts providing new molecular insights into prostate and other cancers will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago and online June 2-6.

• New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification

  4/17/2023

  Veracyte, Inc. announced that new data published in European Urology Oncology suggest the Decipher Prostate Genomic Classifier could help identify prostate cancer patients who have micrometastatic disease and who may therefore benefit from systemic treatment intensification.

• Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023

  4/13/2023

  Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2023 after the close of market on Thursday, May 4, 2023.

• Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting

  4/12/2023

  Veracyte, Inc . (Nasdaq: VCYT) announced today that seven abstracts highlighting new data from studies of the company’s Decipher urologic cancer tests will be presented at the American Urological Association (AUA) Annual Meeting, taking place April 28-May 1, 2023.

• Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners

  3/15/2023

  Veracyte, Inc. announced that three abstracts highlighting the company’s unique, multi-omics capabilities and offerings for biopharmaceutical partners will be presented at the American Association for Cancer Research Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida.

• Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank

  3/11/2023

  Veracyte, Inc. outlined the company’s cash, cash equivalents and short-term investment status in light of the events surrounding Silicon Valley Bank.

• Veracyte to Participate in Upcoming March 2023 Investor Conferences

  2/27/2023

  Veracyte, Inc. announced that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences.

• Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results

  2/22/2023

  Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2022.

• Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer

  2/15/2023

  Veracyte, Inc. (Nasdaq: VCYT) today announced that data published in the International Journal of Radiation Oncology, Biology, Physics (aka, “The Red Journal”) demonstrate that the company’s Decipher Prostate Genomic Classifier can improve risk stratification among men with clinically high-risk prostate cancer.

• New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment

  2/13/2023

  Veracyte, Inc. (Nasdaq: VCYT) announced new data being presented this week at the 2023 American Society of Clinical Oncology Genitourinary (ASCO GU) Symposium which demonstrate that a gene expression signature derived from the company’s proprietary Decipher Genomics Resource for Intelligent Discovery (GRID) database may help physicians further personalize treatment for men with prostate cancer, based on their tumor’s molecular subtype.

• Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023

  2/6/2023

  Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2022 after the close of market on Wednesday, February 22, 2023.

• Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules

  2/1/2023

  Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules.

• Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium

  2/1/2023

  Veracyte, Inc. (Nasdaq: VCYT) today announced that six abstracts highlighting new data focused on the company’s Decipher urologic cancer testing offerings will be presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium, taking place in San Francisco, Calif. and online, February 16-18, 2023.

• Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis

  12/15/2022

  Veracyte, Inc. announced that findings demonstrating the strong real-world performance of the Afirma Genomic Sequencing Classifier were published in The Journal of Clinical Endocrinology & Metabolism.

• Veracyte Announces Third Quarter 2022 Financial Results

  11/2/2022

  Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2022.

• Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting

  11/1/2022

  Veracyte, Inc. announced that three abstracts highlighting the company’s unique, multi-omics immuno-oncology capabilities and offerings will be presented at the Society for Immunotherapy of Cancer’s 37th Annual Meeting & Pre-Conference Programs, taking place November 8-12, 2022, in Boston.

• Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference

  10/27/2022

  Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Credit Suisse 31st Annual Healthcare Conference on Tuesday, November 8, at 1:25 p.m. Eastern Time.

• New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy

  10/25/2022

  Veracyte, Inc . (Nasdaq: VCYT) announced new data demonstrating that a genomic signature derived from the company’s Decipher GRID database could help determine which men experiencing prostate cancer progression following radical prostatectomy (RP).

• Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer

  10/24/2022

  Veracyte, Inc. (Nasdaq: VCYT) today announced data that provide new insights into thyroid tumor behavior.

• New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

  10/18/2022

  Veracyte, Inc. (Nasdaq: VCYT) today announced that two abstracts highlighting the clinical value of the company’s Envisia Genomic Classifier and Percepta Nasal Swab tests in interstitial lung disease (ILD) and lung cancer, respectively, were presented as posters today at the American College of Chest Physicians (CHEST) Annual Meeting 2022.